Financial Performance - The company's operating revenue for the first half of 2018 was CNY 4,082,862,397.77, representing a 16.61% increase compared to CNY 3,501,194,865.91 in the same period last year[19]. - The net profit attributable to shareholders of the listed company was CNY 287,965,689.53, up 15.92% from CNY 248,416,274.51 in the previous year[19]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was CNY 278,416,788.14, reflecting a 10.83% increase from CNY 251,218,606.13 in the same period last year[19]. - The basic earnings per share for the first half of 2018 was CNY 0.72, an increase of 4.35% compared to CNY 0.69 in the same period last year[21]. - The weighted average return on net assets decreased to 9.93%, down 7.27 percentage points from 17.20% in the previous year[21]. - The company achieved a revenue of ¥4,082,862,397.77, representing a year-on-year growth of 16.61%[36]. - The net profit attributable to the parent company was ¥287,965,689.53, an increase of 15.92% compared to the previous year[36]. - The total profit for the current period was ¥383,661,345.79, an increase of 15.59% from ¥332,027,961.70 in the previous period[95]. Cash Flow and Assets - The net cash flow from operating activities decreased by 36.73% to CNY 162,741,116.61, down from CNY 257,215,805.59 in the previous year[19]. - The total assets at the end of the reporting period were CNY 5,769,048,425.71, a decrease of 0.92% from CNY 5,822,764,034.08 at the end of the previous year[20]. - The company's other receivables increased by 30.92% to 210,458,052.01 yuan, primarily due to an increase in store deposits[51]. - The company's intangible assets rose by 123.86% to 255,470,305.59 yuan, mainly from the acquisition of land for the operation center[51]. - The company reported a net cash flow from operating activities of ¥162,741,116.61, a decrease of 36.73%[43]. - Current assets totaled RMB 3,770,076,858.45, a decrease of 7.0% from RMB 4,054,881,400.85 at the beginning of the period[87]. - Cash and cash equivalents increased to RMB 1,181,363,898.52, up 9.2% from RMB 1,081,501,490.47[87]. - Total liabilities decreased to RMB 2,904,108,954.42, down 3.8% from RMB 3,020,092,624.34[89]. Store Expansion and Market Strategy - The company opened 449 new stores in six provinces, bringing the total number of stores to 3,404 as of June 30, 2018[27]. - Membership sales accounted for 83.6% of total sales, indicating a strong customer loyalty[33]. - The company is actively expanding its retail network and enhancing its brand presence in underdeveloped areas, particularly in Guangxi, Henan, and Jiangxi[32]. - The company expanded its DTP pharmacy model and opened 24 new hospital-side stores, bringing the total to 284[36]. - The company is focusing on expanding its logistics and information systems to improve management efficiency and support business operations[40]. - The company is actively developing new business lines, including pharmaceutical e-commerce and traditional Chinese medicine services[36]. Acquisitions and Investments - The company acquired assets and businesses from six stores for RMB 1.8 million and completed the transaction in April 2018[30]. - The company purchased a 19% stake in Baoding Shengshi Huaxing Pharmaceutical Chain Co., Ltd. for RMB 27.17 million, completed in February 2018[30]. - The company engaged in the acquisition of 15 stores from Zhanjiang Hongzhong Pharmacy Co., Ltd. for RMB 19.488 million, with completion in July 2018[30]. - The company invested RMB 4.491 million to acquire a 4.99% stake in Beijing Lasso Biotechnology Co., Ltd. in May 2018[30]. - The company is considering strategic acquisitions to bolster its market position, with a target of acquiring two smaller firms by the end of the year[67]. Shareholder and Management Information - No profit distribution or capital reserve transfer plan proposed for the half-year period[61]. - The actual controller and shareholders committed to not transferring or entrusting the management of their shares for 36 months post-listing[62]. - The company reported a lock-up period of 36 months for major shareholders, during which they cannot transfer or manage their shares[64]. - The company appointed Tianjian Accounting Firm as the auditor for 2018, approved at the 2017 annual general meeting[69]. - The company appointed Peng Guangzhi as the new CFO on May 10, 2018, following the resignation of Yang Tian[82]. Risks and Market Conditions - The company faces risks from intensified market competition as the pharmaceutical retail industry consolidates, with larger enterprises leveraging capital and brand advantages[54]. - The introduction of foreign capital and advanced management concepts is expected to enhance the overall pharmaceutical service level in China, increasing market competition[55]. - The company plans to strengthen its existing market layout and improve professional pharmaceutical services to enhance competitive strength and market share[55]. - The company is implementing measures to adapt to regulatory changes, including improving internal management and investing in artificial intelligence to enhance operational efficiency[57]. Accounting Policies and Financial Reporting - The financial statements comply with the requirements of enterprise accounting standards, reflecting the company's financial status accurately[118]. - The company applies the accounting treatment for business combinations under common control by measuring the acquired assets and liabilities at their book value in the consolidated financial statements of the ultimate controlling party[122]. - The company recognizes revenue from the sale of goods when the main risks and rewards of ownership are transferred to the buyer, and the revenue amount can be reliably measured[171]. - The company recognizes provisions for obligations arising from guarantees, litigation, product quality assurance, and loss contracts when the obligation is measurable and likely to result in an outflow of economic benefits[167].

Financial Performance - The company achieved a net profit attributable to the parent company of RMB 474,960,964.97 for the year 2017[5]. - The total distributable profit for shareholders at the end of 2017 was RMB 1,302,292,747.89, after accounting for the statutory surplus reserve[5]. - The company's operating revenue for 2017 was approximately ¥7.42 billion, representing an 18.29% increase compared to ¥6.27 billion in 2016[22]. - Net profit attributable to shareholders increased by 10.41% to approximately ¥475 million in 2017 from ¥430 million in 2016[22]. - The net profit after deducting non-recurring gains and losses rose by 7.92% to approximately ¥473 million in 2017[22]. - The net cash flow from operating activities increased by 29.21% to approximately ¥640 million in 2017, up from ¥496 million in 2016[22]. - The company's total assets grew by 62.64% to approximately ¥5.82 billion at the end of 2017, compared to ¥3.58 billion at the end of 2016[22]. - The net assets attributable to shareholders surged by 108.96% to approximately ¥2.75 billion at the end of 2017, up from ¥1.32 billion at the end of 2016[22]. - Basic earnings per share increased by 5.88% to ¥1.26 in 2017, compared to ¥1.19 in 2016[23]. - The weighted average return on equity decreased by 13.68 percentage points to 24.28% in 2017 from 37.96% in 2016[23]. Dividend Policy - The board proposed a cash dividend of RMB 6.00 per 10 shares, totaling RMB 240,006,000, to be distributed to all shareholders[5]. - For the fiscal year 2017, the company plans to distribute cash dividends of RMB 6.00 per 10 shares, totaling RMB 240,006,000, which represents 50.54% of the net profit attributable to shareholders[91]. - The cash dividend policy stipulates that at least 20% of the annual distributable profit will be distributed as cash dividends, with a minimum of 80% for mature companies without major capital expenditures[90]. Operational Developments - The company opened new stores and made acquisitions, contributing to revenue growth[23]. - The company completed 9 mergers and acquisitions in the industry during the reporting period, involving 231 stores, with a total investment of approximately RMB 3,150 million for one equity investment and cash acquisitions totaling RMB 13,836 million for land use rights[33][36]. - The company added 633 new stores during the reporting period, with significant revenue increases in regions such as Guangxi (36.79% YoY) and Henan (54.39% YoY), enhancing its operational scale and bargaining power[38]. - The company has a total of 3,146 licensed stores, with 2,985 currently operating, indicating a strong retail network presence across several provinces[38]. - The company has implemented a standardized management system to enhance operational efficiency, including upgrades to existing stores to attract new customers[39]. - The company has developed a mature membership management system, significantly increasing customer loyalty and satisfaction through targeted activities[40]. Risk Management - There were no significant risks that materially affected the company's operations during the reporting period[8]. - The company has outlined various risks and countermeasures in the operational discussion section of the report[8]. - The company is committed to complying with national policies and enhancing internal management systems to mitigate risks associated with regulatory changes[87]. - The company faces risks related to rapid expansion, which may pressure short-term performance, particularly in saturated markets[88]. Governance and Compliance - The report includes a standard unqualified audit opinion from Tianjian Accounting Firm[4]. - The company maintains a commitment to transparency and accuracy in its financial reporting, as stated by its management[4]. - The company has established a comprehensive internal management policy to negotiate better cost advantages with key clinical product manufacturers[87]. - The company has retained Tianjian Accounting Firm as its auditor for the 2017 fiscal year, with an audit fee of RMB 1,100,000[103]. - The company has not reported any significant accounting errors or changes in accounting estimates that would affect its financial reporting[101]. Shareholder Commitments - The actual controller and shareholders committed to not transferring or entrusting others to manage their shares for a period of 36 months from the date of the stock listing[94]. - The shareholders' commitment includes a provision that any share reduction must not be below the issue price, ensuring price stability[94]. - If the closing price of the stock falls below the issue price for 20 consecutive trading days, the lock-up period will be automatically extended by 6 months[94]. - The company has a strategy in place to ensure that the commitments made by its major shareholders are strictly adhered to, enhancing investor confidence[93]. Community Engagement and Social Responsibility - The company has donated over RMB 25 million to support public welfare initiatives, including poverty alleviation and disaster relief efforts[117]. - The company has established a mutual aid fund to assist employees facing hardships, demonstrating its commitment to social responsibility[117]. - The company is actively involved in various community and charitable activities, promoting social harmony and public health awareness[117]. Future Outlook - The company aims to open approximately 700 self-built stores and acquire around 800 stores nationwide in 2018, further expanding market share[84]. - The company is focusing on expanding its logistics system and information technology, including the completion of key projects like ERP and BI systems[48]. - The company plans to enhance product categories and explore potential small categories to improve profitability and market share[84]. - The company anticipates increased competition in the pharmaceutical retail sector due to rising market concentration and the entry of foreign capital, which may impact overall service levels[86].

Financial Performance - Operating revenue for the period reached CNY 2,033,957,620.78, representing a year-on-year increase of 17.11%[5] - Net profit attributable to shareholders was CNY 147,008,882.02, up 25.39% from the same period last year[5] - Basic earnings per share increased by 12.12% to CNY 0.37[5] - The company reported a net profit excluding non-recurring items of CNY 138,917,549.20, an increase of 16.54% year-on-year[5] - Net profit attributable to the parent company increased to CNY 189,193,109.53, representing a growth of 20.5% year-over-year[27] - The net profit for Q1 2018 reached CNY 145,653,653.49, representing a growth of 24.5% from CNY 116,967,840.64 in Q1 2017[28] - The total profit for Q1 2018 was CNY 197,020,252.76, compared to CNY 159,219,970.92 in Q1 2017, marking a 23.7% increase[28] - The company's operating profit for Q1 2018 was CNY 195,853,191.43, an increase of 23.0% from CNY 159,264,141.19 in the same quarter last year[28] - The total comprehensive income for Q1 2018 was CNY 145,653,653.49, compared to CNY 116,967,840.64 in the previous year, indicating a growth of 24.5%[29] Cash Flow - The net cash flow from operating activities was CNY 5,188,605.24, a significant decrease of 96.34% compared to the previous year[5] - Cash flow from operating activities for Q1 2018 was CNY 2,353,269,812.76, up from CNY 2,015,334,696.50 in Q1 2017, reflecting a growth of 16.7%[33] - Net cash flow from operating activities was CNY -88,122,872.75, a decline from CNY 27,913,955.76 in the previous year[36] - Operating cash inflow totaled CNY 2,848,635,865.40, an increase from CNY 2,367,561,760.96 in the previous period, reflecting a growth of approximately 20.3%[34] - The ending cash and cash equivalents balance was CNY 591,271,490.02, compared to CNY 356,797,625.95 at the end of the previous period, reflecting an increase of approximately 65.7%[35] Assets and Liabilities - Total assets at the end of the reporting period were CNY 5,664,048,219.13, a decrease of 2.73% compared to the end of the previous year[5] - The total assets amounted to ¥5,664,048,219.13, a decrease from ¥5,822,764,034.08 at the beginning of the year[19] - Total liabilities decreased to CNY 2,640,944,435.88 from CNY 2,833,087,197.88 at the start of the year, reflecting a reduction of 6.8%[25] - The total current liabilities were ¥451,079,150.79, down from ¥486,379,150.79 at the beginning of the year[19] - The company's cash and cash equivalents were CNY 583,957,199.74, down from CNY 636,782,412.94 at the beginning of the year[23] - Accounts receivable increased to CNY 923,231,048.60 from CNY 841,624,703.57, indicating a rise of 9.7%[23] - Inventory decreased to CNY 593,447,718.49 from CNY 749,247,037.41, a decline of 20.8%[23] - The company reported a total equity of CNY 1,759,578,809.36, up from CNY 1,720,572,782.71 at the beginning of the year, reflecting a growth of 2.3%[25] Shareholder Information - The number of shareholders at the end of the reporting period was 7,772[11] - The top three shareholders held a combined 62.55% of the shares, with the largest shareholder holding 22.50%[11] Other Financial Metrics - The weighted average return on equity decreased by 3.31 percentage points to 5.20%[5] - Non-recurring gains and losses totaled CNY 8,091,332.82 for the period[8] - The goodwill increased by 32.81% to ¥214,882,451.07 due to the acquisition of non-similar control enterprises[14] - Employee compensation payable decreased by 47.46% to ¥91,374,206.00 primarily due to the inclusion of 2017 year-end bonuses in the initial amount[15] - Tax payable increased by 33.87% to ¥120,850,667.54 mainly due to the provision for income tax in the first quarter[15] - The company received government subsidies related to assets amounting to ¥29,759,000.00, reflecting a 30.76% increase[15] Store Operations - The number of direct-operated stores reached 3,234, with 263 new stores added in Q1 2018, including 130 self-built and 133 acquired stores[16] - The total operating area of stores in South China was 242,691 square meters, with an average monthly revenue per square meter of ¥2,767.93[17] - Total operating costs for Q1 2018 were CNY 1,844,764,511.25, up 16.9% from CNY 1,576,918,510.76 in Q1 2017[27]

Financial Performance - Operating revenue for the first nine months reached CNY 5,299,396,522.65, a 15.68% increase year-on-year[6] - Net profit attributable to shareholders increased by 9.49% to CNY 366,703,867.43 for the first nine months[6] - Basic earnings per share rose by 8.79% to CNY 0.99[7] - The net profit for the first nine months was ¥488,074,683.90, compared to ¥444,934,759.25 in the same period last year, indicating a growth of 9.6%[23] - The company's net profit for Q3 2017 was CNY 118,287,592.92, an increase from CNY 114,178,376.69 in the same period last year, representing a growth of approximately 2.45%[25] - The total profit for Q3 2017 was CNY 36,400,285.55, compared to CNY 28,988,756.24 in the same quarter of the previous year, marking an increase of about 25%[27] Assets and Liabilities - Total assets increased by 47.90% to CNY 5,294,833,946.97 compared to the end of the previous year[6] - The company’s total liabilities amounted to CNY 2,610,344,443.91, up from CNY 2,238,044,173.54, representing a rise of 16.66%[17] - The company's fixed assets rose to CNY 657,214,993.33, a 74.95% increase from CNY 375,658,601.03[16] - Total assets reached CNY 5,294,833,946.97, up from CNY 3,580,128,741.54, reflecting a growth of 47.88%[18] - The total equity of the company increased to ¥1,664,530,935.73 from ¥638,408,570.12, representing a growth of 161.5%[21] Cash Flow - Cash flow from operating activities increased by 11.35% to CNY 482,411,110.16 for the first nine months[6] - The company reported a net cash flow of CNY 1,019,141,658.95, a significant increase of 706.78% compared to CNY 126,322,659.38 in the previous year[13] - Cash flow from operating activities for the first nine months of 2017 was CNY 6,106,806,250.33, an increase from CNY 5,216,418,875.72 in the same period last year, reflecting a growth of approximately 17%[30] - The net cash flow from operating activities for Q3 2017 was ¥482,411,110.16, an increase of 11.3% compared to ¥433,255,862.85 in Q3 2016[31] - The net cash flow from financing activities for the first nine months of 2017 was ¥1,034,378,899.10, compared to ¥154,770,721.68 in the same period last year[35] Shareholder Information - The number of shareholders reached 16,365 by the end of the reporting period[8] - The top three shareholders, all natural persons, hold a combined 62.55% of the shares[9] Inventory and Current Assets - Inventory levels increased to CNY 1,571,559,945.24, compared to CNY 1,304,759,216.79, indicating a growth of 20.51%[16] - Other current assets surged by 692.61% to CNY 567,015,622.57, primarily due to temporarily idle funds[11] - Current assets totaled ¥3,392,520,136.09, a significant rise of 79.9% from ¥1,885,207,177.05 at the start of the year[20] - Inventory levels rose to ¥664,437,561.98, up 22.8% from ¥541,126,314.85 at the beginning of the year[20] Operating Costs and Profit Margins - Total operating costs for the third quarter were ¥1,643,206,502.74, up 10.9% from ¥1,480,820,014.99 year-over-year[22] - The company reported a gross profit margin of approximately 10.7% for the third quarter, compared to 10.1% in the previous year[22] - The gross profit margin for Q3 2017 was approximately 21.5%, with operating costs amounting to CNY 748,967,380.93 against revenues of CNY 954,545,228.89[26] Future Plans - The company plans to continue expanding its market presence and investing in new product development to drive future growth[22]

Financial Performance - The company's operating revenue for the first half of 2017 was CNY 3,501,194,865.91, representing an increase of 18.65% compared to CNY 2,950,763,314.66 in the same period last year[16]. - The net profit attributable to shareholders of the listed company was CNY 248,416,274.51, up 14.45% from CNY 217,051,505.54 year-on-year[16]. - The net profit after deducting non-recurring gains and losses was CNY 251,218,606.13, reflecting an increase of 11.24% compared to CNY 225,830,073.86 in the previous year[16]. - The net cash flow from operating activities was CNY 257,215,805.59, showing a slight increase of 0.65% from CNY 255,561,501.65 in the same period last year[16]. - The total assets at the end of the reporting period were CNY 3,988,429,375.64, which is an increase of 11.40% from CNY 3,580,128,741.54 at the end of the previous year[16]. - The net assets attributable to shareholders of the listed company increased by 19.19% to CNY 1,570,261,608.58 from CNY 1,317,395,079.33 at the end of the previous year[16]. - The basic earnings per share for the first half of 2017 was CNY 0.69, a 15.00% increase from CNY 0.60 in the same period last year[17]. - The weighted average return on net assets decreased by 3.27 percentage points to 17.20% from 20.47% in the previous year[17]. - The growth in operating revenue was primarily driven by the performance of existing stores and contributions from new openings and acquisitions[17]. Market and Industry Trends - The urbanization rate in China reached 57.35% by the end of 2016, with urban residents spending an average of 1,193 yuan on healthcare, compared to 722 yuan for rural residents, indicating a growing market for pharmaceutical retail[28]. - The aging population in China is increasing, with the proportion of individuals aged 65 and above reaching 10.8% in 2016, driving higher demand for pharmaceuticals[30]. - The healthcare expenditure of urban residents continues to grow, reflecting an increasing awareness of health maintenance and disease treatment among consumers[27]. - The number of participants in urban basic medical insurance reached 74.39 million in 2016, indicating a growing coverage and investment in the healthcare sector by the government[29]. - The government has implemented policies to support the retail pharmacy industry, including encouraging integrated operations and collaboration with medical institutions and e-commerce[23]. Company Operations - The company operates 2,625 retail chain stores across multiple provinces, including Guangdong, Guangxi, Henan, Fujian, Jiangxi, and Zhejiang, focusing on direct sales of traditional Chinese medicine and health products[22]. - The company has established a strong online sales channel through its own e-commerce platform and partnerships with other platforms to enhance customer service and meet online purchasing needs[22]. - The company has established a logistics distribution system with a self-distribution ratio of 80%, ensuring timely and reliable delivery[35]. - The company maintains stable partnerships with over 2,000 suppliers, including the top 100 pharmaceutical companies in China[36]. - The company has implemented a standardized management system for its chain stores, enhancing operational efficiency and scalability[33]. - The company is focusing on e-commerce development, improving its self-built platform and participating in third-party promotions[43]. - The company plans to continue its expansion strategy, particularly near hospitals, and is actively seeking acquisition opportunities[44]. - The company aims to enhance customer satisfaction and repurchase rates through the implementation of a CRM system[44]. - The company is upgrading its traditional Chinese medicine production facilities to improve product quality and competitiveness[43]. Financial Risks and Challenges - The company reported no significant risks that could materially affect its operations during the reporting period[3]. - The company faces risks from intense competition in the pharmaceutical retail industry, which may impact its market share and profitability[53]. - The rapid growth of e-commerce in the pharmaceutical sector poses a risk to traditional retail pharmacies, with online sales increasing from CNY 0.015 billion in 2010 to CNY 15.2 billion in 2015[53]. - The company is subject to potential price reductions in pharmaceuticals due to regulatory measures, which could compress profit margins across the industry[54]. - Risks associated with mergers and acquisitions include potential failure in business integration and performance improvement, which could negatively impact operational results[56]. - The company plans to expand into new regional markets, which poses risks due to differences in economic development, healthcare policies, and consumer habits across regions[56]. Future Outlook and Strategy - The company provided a positive outlook for the second half of 2017, projecting a revenue growth of 20% to 30% compared to the first half[62]. - New product launches are expected to contribute significantly to revenue, with three new pharmaceutical products scheduled for release by the end of 2017[62]. - The company is investing in research and development, allocating 10% of its revenue to R&D efforts to enhance product offerings and innovation[62]. - Market expansion plans include entering two new provinces in China by the end of 2017, aiming to increase market share by 15% in those regions[62]. - The company is considering strategic acquisitions to enhance its product portfolio, with a focus on companies that specialize in innovative healthcare solutions[62]. - The management emphasized the importance of digital transformation, planning to invest in technology upgrades to improve operational efficiency and customer engagement[62]. - The company aims to improve gross margins by 5% through cost control measures and optimizing supply chain management[62]. - A commitment to sustainability was highlighted, with plans to reduce carbon emissions by 20% over the next three years as part of the corporate social responsibility strategy[62]. Shareholder and Governance Matters - The company reported a net asset value per share that will be adjusted based on profit distribution, capital reserve transfer, and other factors affecting total net assets or shares[63]. - The company has committed to not transferring or entrusting the management of its shares for a period of 36 months from the date of listing[63]. - If the closing price of the company's stock falls below the issue price for 20 consecutive trading days, the lock-up period for certain shareholders will be extended by 6 months[63]. - The company plans to implement specific measures to stabilize its stock price if the closing price falls below the net asset value per share[64]. - The company will announce a stock repurchase plan if the stock price stabilization measures are not successful within 60 trading days[64]. - The company has committed to not engaging in any competitive business activities that may conflict with its operations[64]. - The company will require its major shareholders to propose a plan to stabilize the stock price within five trading days if certain conditions are met[64]. - The company has established a commitment to maintain the stability of its stock price for three years from the date of listing[64]. - The company will disclose any adjustments to the net asset value per share in accordance with relevant regulations[64]. Compliance and Legal Matters - The company has renewed its audit engagement with Tianjian Certified Public Accountants for the year 2017, maintaining continuity in its financial oversight[67]. - There are no significant litigation or arbitration matters reported during the reporting period, indicating a stable legal environment for the company[67]. - The company has not disclosed any major related party transactions during the reporting period, reflecting a focus on transparency and governance[68]. - The company has made commitments to not occupy assets of its subsidiaries, ensuring financial integrity and accountability[66]. - The company plans to transfer ownership of certain properties to ensure legal compliance by December 31, 2020, which may impact future operational strategies[65]. - The company has not reported any significant changes in its employee incentive plans, suggesting stability in its workforce management strategies[68]. - The company has engaged in a related party transaction involving the acquisition of real estate, valued at approximately 1,349.73 million RMB, which may enhance its asset base[68]. - The company has committed to not increasing rental prices for properties leased during the transition period, ensuring cost stability for its operations[65]. - The company has not faced any penalties or corrective actions from regulatory bodies during the reporting period, indicating a strong compliance record[67]. Accounting and Financial Reporting - The company did not report any changes in accounting policies or estimates during the reporting period[72]. - There were no significant accounting errors that required retrospective restatement during the reporting period[72]. - The company has not disclosed any major related party transactions during the reporting period[70]. - The company did not have any strategic investors or general legal entities becoming top 10 shareholders due to new share placements[81]. - There were no changes in the controlling shareholder or actual controller during the reporting period[81]. - The company has not reported any significant contracts or their performance during the reporting period[72]. - The company did not engage in any poverty alleviation work during the reporting period[71]. - The total current assets as of June 30, 2017, amounted to CNY 2,661,945,657.77, an increase from CNY 2,404,365,368.01 at the beginning of the period, representing a growth of approximately 10.7%[87]. - The total assets of the company reached CNY 3,988,429,375.64, up from CNY 3,580,128,741.54, indicating an increase of about 11.4%[89]. - The company's total liabilities increased to CNY 2,375,293,867.25 from CNY 2,238,044,173.54, reflecting a rise of approximately 6.1%[89]. - The cash and cash equivalents at the end of the period were CNY 812,995,839.82, compared to CNY 668,447,785.41 at the beginning, marking a growth of around 21.6%[87]. - The accounts receivable increased significantly to CNY 209,392,354.67 from CNY 206,813,032.95, showing a slight increase of about 1.3%[87]. - The inventory balance rose to CNY 1,392,741,206.04 from CNY 1,304,759,216.79, which is an increase of approximately 6.7%[87]. - The company's equity attributable to shareholders increased to CNY 1,570,261,608.58 from CNY 1,317,395,079.33, representing a growth of about 19.2%[89]. - The non-current assets totaled CNY 1,326,483,717.87, up from CNY 1,175,763,373.53, indicating an increase of approximately 12.8%[88]. - The short-term borrowings rose to CNY 491,221,463.39 from CNY 351,577,300.62, reflecting an increase of about 39.7%[88]. - The company appointed new independent directors and a vice president, indicating a strategic shift in management[86].